Cubicin and Cefotaxime drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cubicin (daptomycin) and Cefotaxime (cefotaxime sodium). Common drug interactions include acute lung injury among females and agranulocytosis among males.

The phase IV clinical study analyzes what interactions people have when they take Cubicin and Cefotaxime. It is created by eHealthMe based on reports of 30 people who take the same drugs from the FDA, and is updated regularly.

What is Cubicin?

Cubicin has active ingredients of daptomycin. It is often used in infection. eHealthMe is studying from 7,991 Cubicin users. Check the latest studies of Cubicin.

What is Cefotaxime?

Cefotaxime has active ingredients of cefotaxime sodium. eHealthMe is studying from 7,559 Cefotaxime users. Check the latest studies of Cefotaxime.

On Jul, 13, 2026

30 people who take Cubicin and Cefotaxime together, and have interactions are studied.

Cubicin and Cefotaxime drug interactions.

What are the common drug interactions of Cubicin and Cefotaxime, by gender? *:

female:

Acute lung injury
Acute respiratory distress syndrome
Hypotension (abnormally low blood pressure)
Lactic acidosis (low ph in body tissues)
Heart rate increased
Staphylococcal infection (an infection with staphylococcus bacteria)
Cardiac failure
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
Disseminated intravascular coagulation (systemic activation of blood coagulation)
Fungal infection

male:

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
Disease progression
Osteitis (a general term for inflammation of bone)
Pneumonia
Procedural site reaction
Abdominal distension
Antibiotic level above therapeutic
Atelectasis neonatal (partial or complete collapse of the lung in newborn)
Blood creatinine increased
Cardiac murmur (an heart sound in valve abnormality)

What are the common drug interactions of Cubicin and Cefotaxime, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Drug ineffective
Drug resistance (reduction in effectiveness of a drug)
Maternal exposure during pregnancy (use of substance during pregnancy)
Neutropenia (an abnormally low number of neutrophils)
Pathogen resistance
Premature delivery

30-39:

Blood creatinine increased
Body temperature increased
Coagulopathy (blood's ability to clot is impaired)
Heart rate increased
Neutropenia (an abnormally low number of neutrophils)
Pseudomembranous colitis (antibiotic-associated diarrhoea (aad), is an infection of the colon)

40-49:

Eosinophil count increased
Lung disorder (lung disease)
Pruritus (severe itching of the skin)
Rash

50-59:

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
Aggression
Cardiac arrest
Cardiac failure
Cerebral ischaemia (insufficient blood flow to the brain to meet metabolic demand)
Disease progression
Nervous system disorder (a general class of medical conditions affecting the nervous system)
Osteitis (a general term for inflammation of bone)
Pneumonia
Procedural site reaction

60+:

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
Hypotension (abnormally low blood pressure)
Cardiac failure
Abdominal distension
Antibiotic level above therapeutic
Atelectasis neonatal (partial or complete collapse of the lung in newborn)
Cardiac murmur (an heart sound in valve abnormality)
Cholestasis (a condition where bile cannot flow from the liver to the duodenum)
Disseminated intravascular coagulation (systemic activation of blood coagulation)
Fungal infection

What are the existing conditions these people have? *

Endocarditis (inflammation in heart muscle): 10 people, 33.33%
Staphylococcal Sepsis (blood infection by an infection with staphylococcus bacteria): 4 people, 13.33%
Staphylococcal Infection (an infection with staphylococcus bacteria): 4 people, 13.33%
Pneumonia: 3 people, 10.00%
Sternitis (inflammation of the sternum): 2 people, 6.67%
Staphylococcus Test Positive: 2 people, 6.67%
Mediastinitis (inflammation of the tissues in the mid-chest): 2 people, 6.67%
Klebsiella Infection: 2 people, 6.67%
Cardiac Infection (an infection of the heart): 2 people, 6.67%
Brain Abscess: 2 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Cubicin and Cefotaxime?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously